Purpose/Objective (s) The role of radiation for pancreatic cancer remains controversial with
heterogeneous clinical response. Characterization of molecular biomarkers that predict …

Purpose The purpose of this study was to determine if somatic mutations are associated with
clinical and pathologic outcomes in patients with borderline resectable pancreatic cancer …

Purpose/Objective (s) The purpose of this study was to determine if mutations in biological
pathways are associated with clinical outcomes in patients with localized pancreatic cancer …

Purpose/Objective (s) The role of radiation for pancreatic cancer remains controversial, with
recent studies showing conflicting results, highlighting the need to develop biomarkers of …

Purpose/Objective (s) KRAS mutations (MUT) are one of the major drivers in pancreatic
ductal adenocarcinoma (PDA) with over 90% of patients having alterations. However, the …

709 Background: Stereotactic body radiotherapy (SBRT) has been incorporated into multi-
modality treatment of locally advanced and borderline resectable pancreatic ductal …

431 Background: Patients (pts) with localized PC do not routinely undergo comprehensive
genomic profiling (CGP) unless they develop recurrent or metastatic disease. KRAS is the …

Introduction/Background: Multimodal neoadjuvant therapy has resulted in increased rates of
histologic response in pancreatic tumors and adjacent lymph nodes. The biologic …

Purpose/Objective (s) Little is known on optimal management of patients with early onset
pancreatic cancer (EOPC), including the role of radiation therapy. As such, we report on a …

Background: Although neoadjuvant therapy for pancreatic cancer (PC) is becoming more
widely accepted, the role of neoadjuvant chemoradiation (cXRT) remains controversial. We …